Claudia M. Aura

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Application of Artificial Intelligence Techniques to Predict Risk of Recurrence of Breast Cancer: A Systematic Review.

Application of Artificial Intelligence Techniques to Predict Risk of Recurrence of Breast Cancer: A Systematic Review.

Journal: Journal of personalized medicine

Published: August 10, 2022

Feature fusion of Raman chemical imaging and digital histopathology using machine learning for prostate cancer detection.

Feature fusion of Raman chemical imaging and digital histopathology using machine learning for prostate cancer detection.

Journal: The Analyst

Published: June 01, 2021

Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer.

Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer.

Journal: Cancers

Published: October 25, 2020

Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells.

Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells.

Journal: Antioxidants (Basel, Switzerland)

Published: February 28, 2020

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 03, 2018

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

Journal: Breast cancer research and treatment

Published: October 14, 2015

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

Journal: Molecular oncology

Published: June 19, 2015

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.

Journal: PloS one

Published: March 26, 2015

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 08, 2015

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 07, 2015

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 04, 2014

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 03, 2014

Showing 1-12 of 20

Last Updated: 09/26/2026